BEAM

26.32

5.56% -1.55

Pre-mercato: 27.10 0.78 +2.96%

Beam Therapeutics Inc (BEAM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BEAM Giù? Forum Previsione

Precedente Chiudi:

$27.87

Aprire:

$28.48

Volume 24 ore:

4.68M

Relative Volume:

1.83

Capitalizzazione di mercato:

$2.66B

Reddito:

$352.57M

Utile/perdita netta:

$-143.01M

Rapporto P/E:

-14.54

EPS:

-1.81

Flusso di cassa netto:

$-153.40M

1 W Prestazione:

+2.21%

1M Prestazione:

+32.39%

6M Prestazione:

+79.90%

1 anno Prestazione:

+14.29%

Intervallo 1D:

$25.62

$28.62

Intervallo di 1 settimana:

$24.67

$28.75

Portata 52W:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Nome

Beam Therapeutics Inc

Settore

Healthcare (1140)

Industria

Biotechnology (637)

Telefono

857-327-8775

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

509

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

BEAM's Discussions on Twitter

Confronta BEAM con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BEAM Beam Therapeutics Inc	26.32	2.82B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-09	Iniziato	Jefferies	Buy
2025-03-28	Aggiornamento	BofA Securities	Neutral → Buy
2025-03-10	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-07-23	Iniziato	H.C. Wainwright	Buy
2024-01-29	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-08	Downgrade	Jefferies	Buy → Hold
2023-10-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Downgrade	Leerink Partners	Outperform → Market Perform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2022-12-20	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Iniziato	Citigroup	Buy
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-01-05	Iniziato	Guggenheim	Buy
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-09-24	Ripresa	Stifel	Buy
2021-09-10	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Redburn	Buy
2021-05-04	Iniziato	RBC Capital Mkts	Sector Perform
2021-03-01	Downgrade	Barclays	Overweight → Equal Weight
2021-02-16	Iniziato	Wells Fargo	Overweight
2021-01-29	Downgrade	JP Morgan	Overweight → Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-08-05	Iniziato	William Blair	Outperform
2020-03-02	Iniziato	Barclays	Overweight
2020-03-02	Iniziato	JP Morgan	Overweight
2020-03-02	Iniziato	Jefferies	Buy
2020-03-02	Iniziato	Wedbush	Outperform

Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

04:16 AM

Should you wait for a breakout in Beam Therapeutics Inc.Weekly Trade Report & Low Risk Entry Point Guides - newser.com

04:16 AM

12:16 PM

Visualizing Beam Therapeutics Inc. stock with heatmapsJuly 2025 Chart Watch & Low Drawdown Momentum Trade Ideas - newser.com

12:16 PM

Oct 12, 2025

Technical analysis overview for Beam Therapeutics Inc. stock2025 Trading Recap & Low Risk High Reward Ideas - newser.com

Oct 12, 2025

What analyst consensus says on Beam Therapeutics Inc. stockMarket Volume Report & Capital Efficient Trading Techniques - newser.com

Oct 12, 2025

Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 12, 2025

Oct 11, 2025

Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves - Yahoo Finance

Oct 11, 2025

Jim Cramer on Beam Therapeutics: “That’s the Speculative Bottom There” - MSN

Oct 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Earns "Buy" Rating from HC Wainwright - MarketBeat

Oct 11, 2025

Oct 10, 2025

Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Oct 10, 2025

Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com

Oct 10, 2025

Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals

Oct 10, 2025

HC Wainwright & Co. Reiterates Beam Therapeutics (BEAM) Buy Recommendation - Nasdaq

Oct 10, 2025

HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus

Oct 10, 2025

What the charts say about Beam Therapeutics Inc. today2025 Price Targets & Community Consensus Picks - newser.com

Oct 10, 2025

Oct 09, 2025

Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 09, 2025

Beam Therapeutics Stock Soars 7.44%, Hits Intraday High of $27.55 - Markets Mojo

Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada

Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Canada

Oct 09, 2025

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent

Oct 09, 2025

Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener

Oct 09, 2025

Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com

Oct 09, 2025

SteelPeak Wealth LLC Invests $391,000 in Beam Therapeutics Inc. $BEAM - MarketBeat

Oct 09, 2025

Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com

Oct 09, 2025

Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com

Oct 09, 2025

Oct 08, 2025

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech

Oct 08, 2025

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga

Oct 08, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent

Oct 08, 2025

What Does Wall Street Think About Beam Therapeutics (BEAM)? - Yahoo Finance

Oct 08, 2025

Oct 06, 2025

Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com

Oct 06, 2025

Oct 03, 2025

Recent Insider Transactions at Beam Therapeutics - TradingView

Oct 03, 2025

Beam Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 03, 2025

Oct 01, 2025

Beam Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating - MSN

Oct 01, 2025

Sep 29, 2025

Beam Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Budget Friendly Capital Growth - earlytimes.in

Sep 29, 2025

What analysts say about Beam Therapeutics Inc stockRelative Strength Index (RSI) & Master Timing Market Moves - earlytimes.in

Sep 29, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - MSN

Sep 29, 2025

Sep 28, 2025

H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum - MSN

Sep 28, 2025

Is Beam Therapeutics Inc a good long term investmentGrowth vs. Value Investing & Affordable Investment Portfolio - earlytimes.in

Sep 28, 2025

Sep 26, 2025